Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer: Clinical Oncology/Epidemiology

A total of 61 eligible patients with metastatic cancer have been treated in a series of Phase II trials of the novel pentacyclic pyrroloquinone, fosquidone. Tumour types were colorectal (23), renal (21), and non small cell lung (17). No patient had received prior chemotherapy. The drug was given int...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 1992-04, Vol.65 (4), p.624-625
Main Authors: Kaye, SB, Brampton, M, Harper, P, Smyth, J, Kerr, DJ, Gore, M, Green, JA, Gilby, E, Crawford, SM, Rustin, GJ
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Cancer Research
clinical-oncology-epidemiology
Drug Resistance
Epidemiology
Molecular Medicine
Oncology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A total of 61 eligible patients with metastatic cancer have been treated in a series of Phase II trials of the novel pentacyclic pyrroloquinone, fosquidone. Tumour types were colorectal (23), renal (21), and non small cell lung (17). No patient had received prior chemotherapy. The drug was given intravenously as a 20 min infusion at the dose of 120 mg-2 on days 1 to 5 every 3 weeks. Treatment was well tolerated; the only significant side effects being mild nausea and generalised musculo-skeletal pains. Response was assessed after two cycles of therapy. No patient achieved an objective partial response. A total of nine patients demonstrated stable disease for a median duration of 11 weeks. Using this schedule of administration, fosquidone has no significant antitumour activity in this group of tumours.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1992.127